The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Capricorn Fund Managers Ltd established a new position in Pfizer Inc. during the fourth quarter, acquiring 165,569 shares. The investment is valued at approximately $4.12 million, marking a significant entry into the pharmaceutical giant's stock. This move followed Pfizer's strong fourth-quarter financial performance, which surpassed analyst estimates for both earnings and revenue. The company reported an EPS of $0.66 and total revenue of $17.56 billion, beating market expectations. Currently, institutional investors hold a dominant position in the company, owning about 68.36% of Pfizer's outstanding shares. This institutional buying activity highlights a positive sentiment toward the company's valuation following its recent earnings beat.
Sign up free to access this content
Create Free Account